{"id":20590,"date":"2026-02-02T12:18:33","date_gmt":"2026-02-02T06:48:33","guid":{"rendered":"https:\/\/trending.niftytrader.in\/?p=20590"},"modified":"2026-02-02T12:18:33","modified_gmt":"2026-02-02T06:48:33","slug":"ipo-lock-in-expiry-stocks","status":"publish","type":"post","link":"https:\/\/www.niftytrader.in\/markets\/ipo-news\/ipo-lock-in-expiry-stocks\/","title":{"rendered":"Lock-In Period Over for Key IPO Stocks: Will Fresh Supply Move the Market?"},"content":{"rendered":"

Today\u2019s trade session isn\u2019t ordinary. Multiple newly listed companies have just seen their shareholder lock-in periods expire<\/strong>, meaning chunks of stock that were not tradable until now<\/em> are finally free to hit the market. That matters because it can tweak supply\/demand dynamics and tilt short-term price moves. So the big question is, will these unlocks shake share prices or simply get absorbed quietly?<\/strong> Let\u2019s walk through what\u2019s happening and what traders and analysts are watching.<\/p>\n

What Just Happened?<\/h2>\n

On 2 February 2026<\/strong>, listed shares of several firms, including Lenskart Solutions<\/strong>, Studds Accessories<\/strong><\/a>, Orkla India<\/strong><\/a>, and Akums Drugs & Pharmaceuticals<\/a>,<\/strong> became eligible for trading after their shareholder lock-ins expired<\/strong>. In simple terms: big chunks of shares that were restricted from selling are now allowed to be sold or traded freely<\/em>.<\/p>\n

Lock-in expiries don\u2019t automatically trigger sell-offs; they just make selling possible without regulatory restriction. Whether holders choose<\/em> to sell is the market\u2019s real test.<\/p>\n

A Quick Look at Each Stock<\/h2>\n

Studds Accessories \u2013 Lock-In Over, But Price Struggles Persist<\/strong><\/h3>\n

For Studds, nearly 1.17 million shares<\/strong> were locked until 2 Feb and are now tradable. The stock has been trading weakly recently, showing investors haven\u2019t been in a hurry to bid prices higher. This isn\u2019t exactly panic selling, but it\u2019s not showing strong buying support either.<\/p>\n

Studds brought in steady subscription and listed in November 2025 at a modest level after a strong IPO interest, but its muted debut and recent sideways movement suggest investors are weighing valuation rather than enthusiasm.<\/p>\n

Will prices slide?<\/em> Likely not dramatically unless large holders decide to offload immediately. Market action so far says calm absorption<\/em> rather than frenzy.<\/p>\n

Lenskart Solutions \u2013 Phased Unlocks Adding Volume<\/strong><\/h3>\n

Lenskart\u2019s anchor and pre-IPO lock-in tranches covering tens of millions of shares were set to end around early February (some were already completed in December). This adds meaningful float to the market.<\/p>\n

Lenskart\u2019s IPO was one of the biggest this year, pulling strong initial subscription, but its listing was weak relative to the issue price,<\/em> underperforming versus expectations despite heavy retail and institutional interest.<\/p>\n

Analyst opinion on Lenskart has been mixed, with some criticizing its lofty valuation<\/strong> and others highlighting its strong brand and growth standing. In fact, some market veterans called high valuations a risk rather than a reward, especially when compared with fundamentals.<\/p>\n

Impact on price?<\/em> Because valuations were already under scrutiny, lock-in expiry might add downside pressure<\/strong> if large holders decide to sell, particularly on any signs of stagnation in retail growth or earnings momentum.<\/p>\n

Orkla India \u2013 Consumer Staples on Watch<\/strong><\/h3>\n

Orkla India\u2019s lock-in for anchor investors also ended around this period. This household brand parent, best known for products like MTR and Eastern spices, has seen some downward pressure in its earnings metrics, with its latest quarterly profits easing compared to last year.<\/p>\n

Staples stocks like Orkla often trade more sluggishly than high-growth names, so the end of lock-in doesn\u2019t always mean big swings. It does<\/em> deserve attention, though, because any additional selling here could weigh on consumer-oriented themes if indices are already shaky.<\/p>\n

Akums Drugs & Pharmaceuticals\u2014Steady Fundamentals Could Cushion Moves<\/strong><\/h3>\n

Akums Drugs went public in mid-2024, and the staggered lock-in schedule means most large blocks have become tradable by now. The company operates in contract development and manufacturing (CDMO), a space with solid long-term demand, and its IPO historically saw strong subscription.<\/p>\n

Even with heavy supply now floating, Akums doesn\u2019t typically trade on speculative momentum like e-commerce plays. Longer-term, analysts see promise in its broad portfolio and CDMO depth, meaning the price reaction, if any, could be measured and not wild.<\/p>\n

What Does This Mean for Share Prices Now?<\/strong><\/h2>\n

Here\u2019s a grounded breakdown:<\/p>\n

    \n
  • \n

    Short-term volatility:<\/strong> Very possible\u2014a rise in tradable supply can<\/em> stir price swings, especially in names with already thin liquidity or bearish sentiment (like Lenskart).<\/p>\n<\/li>\n

  • \n

    Studds:<\/strong> More floating stock is available, but lack of strong buying interest means it\u2019s more likely to drift lower or range<\/em> than tank.<\/p>\n<\/li>\n

  • \n

    Lenskart:<\/strong> Biggest candidate for choppiness\u2014valuation concerns, and now more sellers means price could test recent support levels.<\/p>\n<\/li>\n

  • \n

    Orkla India & Akums Drugs:<\/strong> Consumer staples and pharma typically see smoother adjustments, so if there\u2019s selling pressure, it\u2019ll likely be modest and digested over time.<\/p>\n<\/li>\n<\/ul>\n

    The Critical Takeaway<\/strong><\/h2>\n

    Lock-in expiry is a supply event<\/strong>, not a guaranteed sell-off trigger. Traders should watch actual sales volume<\/em> and how stock prices react in early trading. If stocks absorb these unlocked shares with rising buy interest, the expiry will go down as a non-event. But if volumes spike on the downside, that tells you new holders are booking profit or reallocating<\/em>.<\/p>\n

    In markets where multiple IPO lock-ins expire together, psychology matters. Sometimes it\u2019s just noise. Other times it\u2019s the reason<\/em> sentiment shifts. Today feels like the latter, a moment where supply dynamics could nudge price behavior even if fundamentals stay unchanged.<\/p>\n

    FAQs:\u00a0<\/strong><\/h2>\n

    Q1: What is a lock-in period for IPO stocks?<\/strong>
    A:<\/strong> A lock-in period is the time during which major shareholders, like promoters or anchor investors, are restricted from selling their shares<\/strong> after an IPO. Once it ends, those shares become tradable.<\/p>\n

    Q2: Which stocks are affected by this lock-in expiry?<\/strong>
    A:<\/strong> Key IPO stocks impacted include Lenskart Solutions, Studds Accessories, Akums Drugs & Pharmaceuticals, and Orkla India<\/strong>. Some have phased expiries, so supply may increase gradually.<\/p>\n

    Q3: Will the end of the lock-in trigger a stock price drop?<\/strong>
    A:<\/strong> Not necessarily. Prices may face short-term volatility<\/strong> due to increased supply, but long-term movement depends on fundamentals, investor sentiment, and trading volume.<\/p>\n

    Q4: How should investors approach these stocks now?<\/strong>
    A:<\/strong> Watch volume spikes, support\/resistance levels, and market sentiment<\/strong>. Stocks with solid fundamentals (like Akums Drugs) may absorb the new supply better than high-valuation names (like Lenskart).<\/p>\n

    Q5: Is this news classified as IPO news?<\/strong>
    A:<\/strong> Yes. Even though the IPO has already occurred, the story relates to post-IPO lock-in expiry<\/strong>, which affects trading and supply dynamics for newly listed shares.<\/p>\n

    Q6: How can I track the impact of lock-in expiry on these stocks?<\/strong>
    A:<\/strong> Follow real-time trading volumes, broker updates, and price action<\/strong> on stock exchanges. News portals and financial trackers like Marketscreener, Groww, and NSE\/BSE listings<\/strong> provide timely insights.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Today\u2019s trade session isn\u2019t ordinary. Multiple newly listed companies have just seen their shareholder lock-in periods expire, meaning chunks of stock that were not tradable until now are finally free to hit the market. That matters because it can tweak supply\/demand dynamics and tilt short-term price moves. So the big question is, will these unlocks […]<\/p>\n","protected":false},"author":11,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1367],"tags":[],"ppma_author":[1523],"class_list":{"0":"post-20590","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ipo-news"}," _eael_post_view_count":0,"authors":[{"term_id":1523,"user_id":11,"is_guest":0,"slug":"nikki","display_name":"Nikki Lodha","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/ae2e265bd56e0e890c866fbaa55d29846ba20cc5372adf666652268816af117e?s=96&d=mm&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/20590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=20590"}],"version-history":[{"count":5,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/20590\/revisions"}],"predecessor-version":[{"id":20595,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/20590\/revisions\/20595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/20596"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=20590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=20590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=20590"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=20590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}